Rúben Silva

Mr. Rúben Silva

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Marco CavacoMarco Cavaco
Marco Cavaco
JVJavier Valle
Javier Valle
RSRúben Silva
Rúben Silva
João Domingos Galamba CorreiaJoão Domingos Galamba Correia
João Domingos Galamba Correia
MCMiguel Castanho
Miguel Castanho
VNVera Neves
Vera Neves
Background: The use of peptides as drug carriers across the blood-brain barrier (BBB) has increased significantly during the last decades. PepH3, a seven residue sequence (AGILKRW) derived from the α-helical domain of the dengue virus type-2 capsid protein, translocates across the BBB with very low toxicity. Somehow predictably from its size and sequence, PepH3 is degraded in serum relatively fast. Among strategies to increase peptide half-life (t1/2), the use of the enantiomer (wholly made of D-amino acid residues) can be quite successful if the peptide interacts with a target in non-stereospecific fashion.Methods: The goal of this work was the development of a more proteolytic-resistant peptide, while keeping the translocation properties. The serum stability, cytotoxicity, in vitro BBB translocation, and internalization mechanism of DPepH3 was assessed and compared to the native peptide.Results: DPepH3 demonstrates a much longer t1/2 compared to PepH3. We also confirm that BBB translocation is receptor-independent, which fully validates the enantiomer strategy chosen. In fact, we demonstrate that internalization occurs trough macropinocytosis. In addition, the enantiomer demonstrates to be non-cytotoxic towards endothelial cells as PepH3.Conclusion: DPepH3 shows excellent translocation and internalization properties, safety, and improved stability. Taken together, our results place DPepH3 at the forefront of the second generation of BBB shuttles.

23 December 2018 in Molecules
Verified
Journal Article
Open access
PDF file
JMJoão Franco Machado
João Franco Machado
RSRúben Silva
Rúben Silva
Rita MeloRita Melo
Rita Melo
João Domingos Galamba CorreiaJoão Domingos Galamba Correia
João Domingos Galamba Correia
Precision medicine relies on individually tailored therapeutic intervention taking into account individual variability. It is strongly dependent on the availability of target-specific drugs and/or imaging agents that recognize molecular targets and patient-specific disease mechanisms. The most sensitive molecular imaging modalities, Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), rely on the interaction between an imaging radioprobe and a target. Moreover, the use of target-specific molecular tools for both diagnostics and therapy, theranostic agents, represent an established methodology in nuclear medicine that is assuming an increasingly important role in precision medicine. The design of innovative imaging and/or theranostic agents is key for further accomplishments in the field. G-protein-coupled receptors (GPCRs), apart from being highly relevant drug targets, have also been largely exploited as molecular targets for non-invasive imaging and/or systemic radiotherapy of various diseases. Herein, we will discuss recent efforts towards the development of innovative imaging and/or theranostic agents targeting selected emergent GPCRs, namely the Frizzled receptor (FZD), Ghrelin receptor (GHSR-1a), G protein-coupled estrogen receptor (GPER), and Sphingosine-1-phosphate receptor (S1PR). The pharmacological and clinical relevance will be highlighted, giving particular attention to the studies on the synthesis and characterization of targeted molecular imaging agents, biological evaluation, and potential clinical applications in oncology and non-oncology diseases. Whenever relevant, supporting computational studies will be also discussed.

16 March 2020 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Rita MeloRita Melo
Rita Melo
ALAgostinho Lemos
Agostinho Lemos
APA. J. Preto
A. J. Preto
BBBeatriz Bueschbell
Beatriz Bueschbell
PMPedro Matos-Filipe
Pedro Matos-Filipe
IMIrina S. Moreira
Irina S. Moreira
Paediatric Acquired ImmunoDeficiency Syndrome (AIDS) is a life-threatening and infectious disease in which the Human Immunodeficiency Virus (HIV) is mainly transmitted through Mother-To- Child Transmission (MTCT) during pregnancy, labour and delivery, or breastfeeding. This review provides an overview of the distinct therapeutic alternatives to abolish the systemic viral replication in paediatric HIV-1 infection. Numerous classes of antiretroviral agents have emerged as therapeutic tools for downregulation of different steps in the HIV replication process. These classes encompass Non- Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs), Nucleoside/Nucleotide Analogue Reverse Transcriptase Inhibitors (NRTIs/NtRTIs), INtegrase Inhibitors (INIs), Protease Inhibitors (PIs), and Entry Inhibitors (EIs). Co-administration of certain antiretroviral drugs with Pharmacokinetic Enhancers (PEs) may boost the effectiveness of the primary therapeutic agent. The combination of multiple antiretroviral drug regimens (Highly Active AntiRetroviral Therapy - HAART) is currently the standard therapeutic approach for HIV infection. So far, the use of HAART offers the best opportunity for prolonged and maximal viral suppression, and preservation of the immune system upon HIV infection. Still, the frequent administration of high doses of multiple drugs, their inefficient ability to reach the viral reservoirs in adequate doses, the development of drug resistance, and the lack of patient compliance compromise the complete HIV elimination. The development of nanotechnology-based drug delivery systems may enable targeted delivery of antiretroviral agents to inaccessible viral reservoir sites at therapeutic concentrations. In addition, the application of Computer-Aided Drug Design (CADD) approaches has provided valuable tools for the development of anti-HIV drug candidates with favourable pharmacodynamics and pharmacokinetic properties.

3 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
RSRúben Silva
Rúben Silva
JMJoão Franco Machado
João Franco Machado
KGKyle Manuel Ferreira Gonçalves
Kyle Manuel Ferreira Gonçalves
FLFrancisco M. Lucas
Francisco M. Lucas
SBSalete Batista
Salete Batista
João Domingos Galamba CorreiaJoão Domingos Galamba Correia
João Domingos Galamba Correia
Considering our interest in the use of peptides as potential target-specific drugs or as delivery vectors of metallodrugs for various biomedical applications, it is crucial to explore improved synthetic methodologies to accomplish the highest peptide crude purity in the shortest time possible. Therefore, we compared “classical” fluorenylmethoxycarbonyl (Fmoc)-solid phase peptide synthesis (SPPS) with ultrasound(US)-assisted SPPS based on the preparation of three peptides, namely the fibroblast growth factor receptor 3(FGFR3)-specific peptide Pep1 (VSPPLTLGQLLS-NH2) and the novel peptides Pep2 (RQMATADEA-NH2) and Pep3 (AAVALLPAVLLALLAPRQMATADEA-NH2), which are being developed aimed at interfering with the intracellular protein-protein interaction(PPI) RANK-TRAF6. Our results demonstrated that US-assisted SPPS led to a 14-fold (Pep1) and 4-fold time reduction (Pep2) in peptide assembly compared to the “classical” method. Interestingly, US-assisted SPPS yielded Pep1 in higher purity (82%) than the “classical” SPPS (73%). The significant time reduction combined with high crude peptide purity attained prompted use to apply US-assisted SPPS to the large peptide Pep3, which displays a high number of hydrophobic amino acids and homooligo-sequences. Remarkably, the synthesis of this 25-mer peptide was attained during a “working day” (347 min) in moderate purity (approx. 49%). In conclusion, we have reinforced the importance of using US-SPPS towards facilitating the production of peptides in shorter time with increased efficacy in moderate to high crude purity. This is of special importance for long peptides such as the case of Pep3.

26 March 2026 in Biologics
Verified
Journal Article
Open access
PDF file
IMIsa Moutinho
Isa Moutinho
RMRafaela Marimon
Rafaela Marimon
RSRúben Silva
Rúben Silva
Célia FernandesCélia Fernandes
Célia Fernandes
Lurdes GanoLurdes Gano
Lurdes Gano
FSFrederico Aires Da Silva
Frederico Aires Da Silva
Background/Objectives: The continuous emergence of immune-evasive SARS-CoV-2 variants underscores the need for adaptable and accessible therapeutics that complement vaccination. Single-domain antibodies (sdAbs) offer advantages in size, stability, and production costs compared to conventional monoclonal antibodies, but their clinical utility is limited by rapid clearance. This study aimed to develop a rabbit-derived sdAb with broad SARS-CoV-2 neutralization capacity and improved pharmacokinetic properties. Methods: A rabbit-derived variable light-chain (VL) sdAb library was constructed and subjected to phage display selection to identify high-affinity binders. Candidate sdAbs were characterized for cross-variant binding and neutralization. The lead sdAb, B3, was fused to the albumin-binding domain (ABD) of the Streptococcus zooepidemicus Zag protein to enhance in vivo half-life. Expression, albumin-binding capacity, and in vitro neutralization were assessed, followed by biodistribution studies in mice. Results: The selected sdAb, B3, showed strong binding and cross-variant neutralization against multiple SARS-CoV-2 lineages, including Delta and Omicron. Fusion to ABD(Zag) preserved neutralization potency, increased expression yields ~5-fold, and enabled cross-species albumin binding. In vivo, B3-ABD(Zag) exhibited markedly extended blood retention, showing a 21.2-fold increase at 24 h post-injection (5.30 vs. 0.25% I.A./g), and reduced renal uptake by 40% compared with unmodified B3. Conclusions: Rabbit-derived VL sdAbs fused to ABD(Zag) provide a promising platform for next-generation SARS-CoV-2 biologics. The enhanced pharmacokinetic profile of B3-ABD(Zag) supports its potential as a scalable therapeutic modality and highlights the broader utility of this approach for future emerging infectious threats.

3 December 2025 in ACS Omega
Verified
Journal Article
Open access
RSRúben Silva
Rúben Silva
CMCristina P. Matos
Cristina P. Matos
CPCatarina Isabel Guilherme Pinto
Catarina Isabel Guilherme Pinto
LGLurdes Gano
Lurdes Gano
JGJoana F. Guerreiro
Joana F. Guerreiro
João Domingos Galamba CorreiaJoão Domingos Galamba Correia
João Domingos Galamba Correia
Metabolic alterations in cancer cells present an opportunity for the development of new targeted radiopharmaceuticals for cancer imaging and therapy. Radiotracers targeting transporters of amino acids (Aa) hold great potential as agents for cancer theranostics but very few Aa-based radiotracers have been explored, even less based on metallic complexes. To address this challenge, we describe herein the (radio)­synthesis and biological characterization of novel [99mTc]­Tc­(I) complexes bearing pendant l- or d-amino acids for SPECT imaging. The complexes of the type fac-[M­(CO)3(k3-L)]+ (ML1-ML8, M = Re, 99mTc) were prepared by reaction of fac-[M­(CO)3(H2O)3]+ with conjugates combining a pyrazolyl-diamine (Pz) chelating unit and both enantiomeric forms (l/d) of Arg (L1/L2), Lys (L3/L4), His (L5/L6) and Trp (L7/L8). The NMR spectral data is compatible with tridentate coordination of the Pz unit in ReL1–ReL4 and ReL6/ReL7. Reaction of L5/L6 with the Re precursor under acidic conditions yielded a major species in which His is directly involved in metal coordination, the so named β-form of ReL5/ReL6. Under basic reaction conditions, an increase of the so named α-species, where the metal center is stabilized by the Pz unit, is observed. All [99mTc]­Tc­(I) complexes, obtained at neutral pH, displayed significantly higher uptake and internalization in a panel of cancer cell lines than the amino acid-free control complex, [ 99m Tc]­TcL0, with [ 99m Tc]­TcL5 and [ 99m Tc]­TcL7 emerging as the best performing molecules. Aimed at assessing the influence of the α/β-[ 99m Tc]­TcL5 ratio in the cellular uptake, we reacted L5 with the [ 99m Tc]­Tc precursor at low or high pH (favoring β-[ 99m Tc]­TcL5 or α-[ 99m Tc]­TcL5, respectively) and evaluated the cell uptake properties of the resulting species. Interestingly, the putative β-[ 99m Tc]­TcL5 species presented an approximately 3× higher uptake than the putative α-[ 99m Tc]­TcL5 radioactive species, surpassing all the other Aa-containing complexes. This result suggests that the pendant Pz unit may act as an uptake vector. Mechanistic studies aimed to understand the biological properties of β-[ 99m Tc]­TcL5 were also performed but we were unable to correlate the uptake with the levels of Aa transporters expression. Considering that β-[ 99m Tc]­TcL5 presented similar uptake in the MCF7 breast and A549 lung cancer cell lines, we assessed its tumor-targeting properties in mouse models bearing these 2 types of cancer xenografts. Low tumor accumulation in the breast cancer model was observed, with overall poor tumor-to-nonorgan ratio. In contrast, the biodistribution results of β-[ 99m Tc]­TcL5 in mice-bearing A549 xenografts were encouraging as moderate tumor accumulation was observed at all time points with promising tumor-to-nontarget-organ ratios. These results lead to the conclusion that the Pz moiety bears unknown/unexplored biological properties that should be further investigated.